enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

– Quarter marked by corporate rebranding and strategic prioritization of development programs – Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential treatment for severe deep venous Chronic Venous Insufficiency (CVI) – Bolstered cash position with recently completed $20 million registered direct offering with leading life sciences investment firm

Daniel Carlson

November 11, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

5 COMMENTS

Todddg November 21, 2021 at 5:39 pm

You need to login to view this content.

Reply
- Daniel Carlson November 21, 2021 at 8:48 pm
  
  You need to login to view this content.
  
  Reply
Todddg November 20, 2021 at 12:30 am

You need to login to view this content.

Reply
- Daniel Carlson November 20, 2021 at 6:54 am
  
  You need to login to view this content.
  
  Reply
  - Todddg November 21, 2021 at 5:35 pm
    
    You need to login to view this content.
    
    Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.